M&A Activity • Jun 27, 2013
M&A Activity
Open in ViewerOpens in native device viewer
STOCKHOLM – June 27, 2013. Two more world class research centers are teaming up with Karolinska Development. Deal flow agreements have been signed with the Italian university hospital Ospedale San Raffaele and the Medical University of Graz in Austria, which enable Karolinska Development to identify investment opportunities among life science innovations emanating from these leading medical research institutions.
Karolinska Development will assist in the evaluation and assessment of new innovations from each institution, and has the opportunity to invest in commercially attractive projects. The institutions will benefit from Karolinska Development's drug and device development expertise and will be offered engagement in any companies created from the collaborations.
"The deal flow agreements with Ospedale San Raffaele and the Medical University of Graz will increase our access to new cutting-edge research projects and thus gives us a broader base of potential investment opportunities. Further, the collaboration underpins the international reputation of Karolinska Development as an investor in the life science sector and as a developer of innovative new treatments", said Torbjörn Bjerke, CEO of Karolinska Development.
Similar deal flow agreements are already established with, among others, Karolinska Institutet in Sweden and Mayo Clinic in the US.
Ospedale San Raffaele is one of the leading research institutions in Europe. The Italian university hospital is the highest ranking Italian biomedical research institute with about 760 research scientists and 680 clinical researchers working at translational programs, engaged in basic and clinical research within gene therapy, stem cells, immunology, neurodegenerative diseases, proteomics, bioinformatics, neurobiology, molecular biology and diabetes. In 2012, Ospedale San Raffaele was involved in more than 700 clinical studies including about 9,500 patients.
The Medical University of Graz is conducting training, education and research at world-class level, focusing on continuous improvement of top quality medicine and surgery. The university is well renowned for its orientation toward the biopsychosocial model. It has enabled approximately 1,480 researchers to work on almost 3,000 research projects and includes three Nobel laureates amongst its alumni.
Torbjörn Bjerke, CEO, Karolinska Development AB Phone: +46 (0)72 744 41 23, e-mail: [email protected]
Robin Wright, CFO, Karolinska Development AB Phone: +44 (0)7720 30 00 25, e-mail: [email protected]
Benjamin Nordin, IRO, Karolinska Development AB Phone: +46 (0)73 093 60 80, e-mail: [email protected]
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 38 projects, of which 16 are in clinical development. For more information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.